National Cancer Institute (NCI) Grants

Open National Cancer Institute (NCI) grants

• NCI SBIR Phase IIB Bridge Award

  Up to $4.5Mopen

  NCI SBIR Phase IIB Bridge Award is sponsored by National Cancer Institute (NCI). Supports the next stage of development for federally funded SBIR Phas...

  cancer_researchbiomedical_researchhealth_disparitiescancerbiotech

• NCI Outstanding Investigator Award (R35)

  Up to $600Kopen

  NCI Outstanding Investigator Award (R35) is a grant from the National Cancer Institute (NCI) that supports investigators with outstanding cancer resea...

  cancer_researchbiomedical_researchhealth_disparitiescanceroncology

• Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)

  Up to $500Kopen

  Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional) is sponsored by National Cancer Institute (NCI). Funds resear...

  cancer_researchpublic_healthclinical_researchcancer riskbariatric surgery

• National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)

  Up to $500Kopen

  National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) is spo...

  cancer_researchclinical_researchprecision_medicinebiomedical_researchcancer

• Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)

  Up to $275KDeadline: Jan 7, 2028open

  Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed) is sponsored by National Cancer Institute (NCI). This...

  biomedical_researchcancer_researchclinical_researchbioengineeringcancer detection

• PA-25-253: Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)

  Up to $275Kopen

  PA-25-253: Exploratory Grants in Cancer Control (R21 Clinical Trial Optional) is sponsored by National Cancer Institute (NCI).

  cancer_researchpublic_healthhealth_disparitiesclinical_researchcancer control

• Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)

  Up to $275Kopen

  Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) is sponsored by Na...

  cancer_researchpublic_healthbiomedical_researchcancerepidemiology

• NCI Mentored Research Scientist Development Award (K01 - Independent Clinical Trial Required)

  Up to $150Kopen

  NCI Mentored Research Scientist Development Award (K01 - Independent Clinical Trial Required) is sponsored by National Cancer Institute (NCI). Provide...

  cancer_researchpublic_healthbiomedical_researchhealth_disparitiescancer

• Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)

  Deadline: Oct 5, 2026open

  This NIH R01 opportunity (PAR-25-221), jointly supported by NCI and NIAAA, funds research on population-level strategies to reduce cancer risk attribu...

  cancer_researchpublic_healthalcoholcancerpublic_health

• Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)

  Deadline: Oct 5, 2026open

  Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) is sponsored by National Ca...

  cancer_researchbiomedical_researchclinical_researchprecision_medicinemammalian models

• Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk (NCI)

  Deadline: Oct 5, 2026open

  Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk (NCI) is sponsored by National Cancer Institute (NCI). This funding oppor...

  cancer_researchenvironmental_justicebiomedical_researchcancer etiologybiomarkers

• Assay Validation of High Quality Markers for Clinical Studies in Cancer (PAR-25-074)

  Deadline: Oct 14, 2026open

  Assay Validation of High Quality Markers for Clinical Studies in Cancer (PAR-25-074) is sponsored by National Cancer Institute (NCI). This UH2/UH3 gra...

  cancer_researchclinical_researchbiomedical_researchprecision_medicineassay validation

• Assay Validation of High Quality Markers for Clinical Studies in Cancer (Clinical Trial Not Allowed) (PAR-25-074)

  Deadline: Oct 15, 2026open

  Assay Validation of High Quality Markers for Clinical Studies in Cancer (Clinical Trial Not Allowed) (PAR-25-074) is sponsored by National Cancer Inst...

  cancer_researchclinical_researchbiomedical_researchprecision_medicinecancer biomarkers

• Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (Clinical Trial Not Allowed) (PAR-24-304)

  Deadline: Oct 15, 2026open

  Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (Clinical Trial Not Allowed) (PAR-24-304) is ...

  cancer_researchbiomedical_researchprecision_medicinebiomarker validationassay development

• NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (PAR-23-286)

  Deadline: Oct 15, 2026open

  NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (PAR-23-286) is sponsored by National Cancer Institute (NCI). This K99/R00 ...

  cancer_researchbiomedical_researchclinical_researchpostdoctoral fellowshipearly career researcher

• Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

  Deadline: Oct 20, 2026open

  Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) is sponsored by National Cancer Inst...

  cancer_researchbiomedical_researchdata_scienceinformaticscancer

• Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) (RFA-CA-27-001)

  Deadline: Nov 11, 2026open

  Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) (RFA-CA-27-001) is sponsored by ...

  cancer_researchbiomedical_researchclinical_researchprecision_medicinecancer

• High-Risk, High-Reward Immunology Innovation (ExCITe)

  Deadline: Nov 17, 2026open

  High-Risk, High-Reward Immunology Innovation (ExCITe) is a grant from the National Cancer Institute (NCI) that funds innovative, exploratory cancer im...

  health_disparitiesinfectious_diseasecancer_researchimmunologyimmune regulation

• Academic-Industrial Partnerships for Translation of in vivo Imaging Systems for Cancer Investigations (R01)

  Deadline: Jan 7, 2027open

  Academic-Industrial Partnerships for Translation of in vivo Imaging Systems for Cancer Investigations (R01) is sponsored by National Cancer Institute ...

  cancer_researchclinical_researchbiomedical_researchin vivo imagingcancer imaging

• NCI - Notice of Special Interest (NOSI): Advancing Diet and Physical Activity Biomarkers for Assessing Lifestyle Interventions in Cancer Prevention and Cancer Interception Research

  Deadline: Jan 8, 2027open

  NCI - Notice of Special Interest (NOSI): Advancing Diet and Physical Activity Biomarkers for Assessing Lifestyle Interventions in Cancer Prevention an...

  cancer_researchnutritionbiomedical_researchpublic_healthbiomarkers

What National Cancer Institute (NCI) funds

Top program areas based on GrantMind's analysis of recent National Cancer Institute (NCI) awards:

How to apply for National Cancer Institute (NCI) grants

Most National Cancer Institute (NCI) applications require: an organizational profile with mission and programs, a project proposal aligned with the funder's stated priorities, a project budget, and supporting attachments (IRS determination letter, board list, recent financials). Federal applicants additionally need a SAM.gov UEI and an active Grants.gov account.